AZ Exercises Caution With COVID Vaccine Safety Pause As Questions Remain Over Vector
Pause Affects All AZD1222 Trials
The clinical pause for AZD1222 errs on the side of caution, but raises questions about the viral vector’s safety.
You may also be interested in...
Quick Listen: Scrip’s Five Must-Know Things
Join us for a quick audio roundup of major events in the global biopharma industry over the past week, as reported by Scrip.
Takeda Vaccines Head: Peer Review Process For COVID-19 Vaccines Must Be 'Very Open'
The president of Takeda’s global vaccines business emphasizes the need to build trust and ensure that pharma is transparent about “what we will and will not know” at the time that COVID-19 vaccines are licensed.
AstraZeneca CEO: 2020 Approval For COVID Vaccine Still Possible
While AZ awaits an independent review, its CEO maintains the vaccine could soon be back on track for a late 2020/early 2021 approval.